Key Events This Week
23 Mar: Bullish momentum confirmed with mojo grade upgrade to Buy
24 Mar: Valuation grade shifts from attractive to fair amid strong fundamentals
25 Mar: Stock rallies further, extending gains despite Sensex strength
27 Mar: Week closes with a mild correction, stock still up 2.60% for the week
23 March 2026: Bullish Momentum and Mojo Grade Upgrade
Fredun Pharmaceuticals began the week on a strong note, closing at Rs.1,686.30, up Rs.35.45 or 2.15% from the previous close. This rise came despite a sharp 3.13% decline in the Sensex, highlighting the stock’s relative strength. The price action was supported by a mojo grade upgrade to Buy, reflecting improved technical indicators and bullish momentum. The stock traded within a range of Rs.1,609.95 to Rs.1,678.95, maintaining proximity to its 52-week high of Rs.1,999.00.
The upgrade was underpinned by positive signals from moving averages, Bollinger Bands, and a bullish monthly MACD, suggesting a strengthening uptrend. The stock’s mojo score of 77.0 further reinforced confidence in its near-term prospects. This technical improvement positioned Fredun favourably within the Pharmaceuticals & Biotechnology sector, which continues to benefit from innovation and growing healthcare demand.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
24 March 2026: Valuation Grade Shifts Amid Strong Fundamentals
The following day, Fredun Pharmaceuticals’ valuation parameters came under scrutiny as the mojo valuation grade shifted from attractive to fair. Despite the positive mojo grade of Buy, the stock’s price-to-earnings (P/E) ratio stood at 27.69, elevated relative to historical averages but still reasonable for a micro-cap pharmaceutical firm. The price-to-book value (P/BV) ratio was 5.74, indicating a premium valuation reflecting investor confidence in the company’s growth and profitability.
Return on equity (ROE) remained robust at 21.61%, while return on capital employed (ROCE) was a strong 20.23%, supporting the premium multiples. The PEG ratio of 0.45 suggested that earnings growth justified the current valuation despite the premium. Comparisons with peers showed Fredun positioned in the upper mid-range of valuation, trading higher than some fair-valued peers but well below very expensive companies in the sector.
This valuation shift signals a maturing market perception, balancing strong operational metrics against a narrowing margin of safety as the stock price advances.
25 March 2026: Continued Price Strength Amid Sensex Rally
On 25 March, Fredun Pharmaceuticals extended its gains, closing at Rs.1,715.55, up Rs.29.80 or 1.77%. This rise occurred alongside a strong Sensex rally of 1.93%, indicating the stock’s ability to capitalise on positive market momentum. Volume was moderate at 8,059 shares, reflecting steady investor interest.
The stock’s performance this day reinforced the bullish technical outlook established earlier in the week, with price action confirming support above key moving averages. The resilience amid broader market strength suggests that Fredun remains a preferred pick within its sector.
Want to dive deeper on Fredun Pharmaceuticals Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
27 March 2026: Mild Correction Closes the Week
The week concluded with a mild correction on 27 March, as Fredun Pharmaceuticals closed at Rs.1,693.75, down Rs.21.80 or 1.27%. This decline came amid a 2.11% drop in the Sensex, reflecting broader market weakness. Volume was 8,464 shares, slightly higher than the previous day, indicating some profit-taking activity.
Despite the pullback, the stock finished the week with a solid 2.60% gain, outperforming the Sensex’s 1.46% decline. The correction may be viewed as a short-term consolidation following the strong rally earlier in the week, with technical indicators still supporting a constructive medium-term outlook.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.1,686.30 | +2.15% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.1,685.75 | -0.03% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.1,715.55 | +1.77% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.1,693.75 | -1.27% | 32,935.19 | -2.11% |
Key Takeaways
Positive Signals: Fredun Pharmaceuticals demonstrated robust relative strength, gaining 2.60% for the week while the Sensex declined 1.46%. The mojo grade upgrade to Buy and a mojo score of 77.0 reflect strong technical momentum. The stock’s valuation, while shifting from attractive to fair, remains supported by solid profitability metrics including a 21.61% ROE and 20.23% ROCE. The PEG ratio of 0.45 indicates earnings growth justifies the current price level.
Cautionary Notes: The valuation premium relative to some peers suggests a reduced margin of safety. The mild correction on the final trading day may signal short-term profit-taking or consolidation. Investors should monitor weekly technical indicators, which show some caution despite the overall bullish monthly trend.
Conclusion
Fredun Pharmaceuticals Ltd’s performance over the week ending 27 March 2026 highlights a stock in a strengthening uptrend, supported by a mojo grade upgrade and solid operational fundamentals. The stock’s ability to outperform the Sensex amid volatile market conditions underscores its resilience and appeal within the Pharmaceuticals & Biotechnology sector. While valuation metrics have moderated, they remain justified by strong profitability and growth prospects. The mild pullback at week’s end suggests a healthy consolidation phase rather than a reversal, maintaining a constructive outlook for the medium term.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
